Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13371-13386

  Lucarelli, Giuseppe ^a   Galleggiante, Vanessa ^a   Rutigliano, Monica ^a   Sanguedolce, Francesca ^b   Cagiano, Simona ^b   Bufo, Pantaleo ^b   Lastilla, Gaetano ^a   Maiorano, Eugenio ^a   Ribatti, Domenico ^a,c   Giglio, Andrea ^a   Serino, Grazia ^a   Vavallo, Antonio ^a   Bettocchi, Carlo ^a   Selvaggi, Francesco Paolo ^a   Battaglia, Michele ^a   Ditonno, Pasquale ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

G6PDH; Glycolysis; Metabolomics; Pentose phosphate pathway; Renal cell carcinoma

Indexed keywords

6 AMINONICOTINAMIDE; AUTOCRINE MOTILITY FACTOR RECEPTOR; CISPLATIN; GLUCOSE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE 6 PHOSPHATE ISOMERASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TRANSKETOLASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; CANCER SPECIFIC SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHICK; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RESISTANCE; EMBRYO; ENZYME INHIBITION; FEMALE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; NEPHRECTOMY; NONHUMAN; OXIDATION REDUCTION STATE; PARTIAL NEPHRECTOMY; PENTOSE PHOSPHATE CYCLE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ENZYMOLOGY; KIDNEY TUMOR; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLUCOSEPHOSPHATE DEHYDROGENASE; GLYCOLYSIS; HUMANS; KIDNEY NEOPLASMS; MALE; METABOLOMICS; MIDDLE AGED; NADP; PENTOSE PHOSPHATE PATHWAY; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 84931055981     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3823     Document Type: Article

References (37)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics 2014. CA Cancer J Clin. 2014; 64:9-29.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996; 335:865-75
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-23
4. Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol. 2008;179:2096-102.
5. Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol. 2004;171:2461-6
6. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:7388-93
7. Lucarelli G, Ditonno P, Bettocchi C, Vavallo A1, Rutigliano M1, Galleggiante V, Larocca AM, Castellano G, Gesualdo L, Grandaliano G, Selvaggi FP, Battaglia M. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. Dis Markers. 2014;2014:689795.
8. Johnson TV, Abbasi A, Owen-Smith A, Young A, Ogan K, Pattaras J, Nieh P, Marshall FF, Master VA. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol. 2010;183:480-5.
9. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11:85-95.
10. Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discov. 2012;2:881-98.
11. Warburg O. On the origin of cancer cells. Science 1956;123:309-14
12. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
13. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11: 325-337.
14. Eggleston LV, Krebs HA. Regulation of the pentose phosphate cycle. Biochem J 1974;138:425-435.
15. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 2012; 53:421-436.
16. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277-85.
17. Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, Adami HO, Lee JE, Lee HM. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013; 132:625-34.
18. Vavallo A, Simone S, Lucarelli G, Rutigliano M, Galleggiante V, Grandaliano G, Gesualdo L, Campagna M, Cariello M, Ranieri E, Pertosa G, Lastilla G, Selvaggi FP, Ditonno P, Battaglia M. Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore). 2014; 93:e183. doi: 10.1097/MD.0000000000000183.
19. Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA. Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. Oncotarget. 2014; 5:5320-34.
20. White NM, Masui O, Desouza LV, Krakovska O, Metias S, Romaschin AD, Honey RJ, Stewart R, Pace K, Lee J, Jewett MA, Bjarnason GA, Siu KW, Yousef GM. Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. Oncotarget. 2014; 5:506-18.
21. Diaz-Moralli S, Tarrado-Castellarnau M, Alenda C, Castells A, Cascante M. Transketolase-like 1 expression is modulated during colorectal cancer progression and metastasis formation. PLoS One. 2011;6:e25323.
22. Sun W, Liu Y, Glazer CA, Shao C, Bhan S, Demokan S, Zhao M, Rudek MA, Ha PK, Califano JA. TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res. 2010;16:857-66.
23. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
24. Wittig R, Coy JF. The role of glucose metabolism and glucose-associated signalling in cancer. Perspect Medicin Chem 2008; 1: 64-82.
25. Semenza GL. HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr. 2007 Jun;39:231-4
26. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2014;2:3.
27. Mazurek S., Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005; 15: 300-308.
28. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-3
29. Vander Heiden MG, Locasale JW, Swanson KD, Sharfi H, Heffron GJ, Amador-Noguez D, Christofk HR, Wagner G, Rabinowitz JD, Asara JM, Cantley LC. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science. 2010;329:1492-9.
30. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL; Tumor and Angiogenesis Research Group.. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumorassociated stroma. Neoplasia 2005;7:1-6
31. Funasaka T, Raz A. The role of autocrine motility factor in tumor and tumor microenvironment. Cancer Metastasis Rev. 2007 Dec;26:725-35
32. Jiang WG, Raz A, Douglas-Jones A, Mansel RE. Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem. 2006;54:231-41.
33. Tsouko E, Khan AS, White MA, Han JJ, Shi Y, Merchant FA, Sharpe MA, Xin L, Frigo DE. Regulation of the pentose phosphate pathway by an androgen receptormTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis. 2014;3:e103
34. Battaglia M, Lucarelli G. The role of renal surgery in the era of targeted therapy: the urologist's perspective. Urologia. 2015. doi: 10.5301/uro.5000105. [Epub ahead of print]
35. Galleggiante V, Rutigliano M, Sallustio F, Ribatti D, Ditonno P, Bettocchi C, Selvaggi FP, Lucarelli G, Battaglia M. CTR2 Identifies a Population of Cancer Cells with Stem-Like Features in Patients with Clear Cell Renal Cell Carcinoma. J Urol 2014; 192: 1831-41
36. Ribatti D, Nico B, Vacca A, Presta M. The gelatin spongechorioallantoic membrane assay. Nat Protoc. 2006;1:85-91.
37. Ribatti D. Chicken chorioallantoic membrane angiogenesis model. Methods Mol Biol. 2012;843:47-57.